Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 44,850
-950 (-2.07%)
Oct 8, 2026, 10:50 AM KST
Hanall Biopharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,280,990 | 2,221,619 | 1,959,952 | 2,245,705 | 902,290 | 1,077,892 | |
Market Cap Growth | 30.26% | 13.35% | -12.72% | 148.89% | -16.29% | -43.84% |
Enterprise Value | 2,295,789 | 2,211,037 | 1,934,197 | 2,185,410 | 836,710 | 991,822 |
Last Close Price | 45800.00 | 43750.00 | 38650.00 | 44300.00 | 17800.00 | 21050.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 640.06 | 3588.03 | 121.16 |
Forward PE | - | 293.05 | 117.15 | 261.09 | 112.30 | 65.12 |
PS Ratio | 14.32 | 14.32 | 14.11 | 16.65 | 8.20 | 10.61 |
PB Ratio | 14.41 | 13.74 | 11.64 | 12.06 | 5.36 | 6.59 |
P/TBV Ratio | 22.07 | 14.13 | 11.96 | 12.18 | 5.43 | 6.68 |
P/FCF Ratio | - | - | 253.93 | 82.47 | 40.22 | - |
P/OCF Ratio | - | - | 209.40 | 75.76 | 35.71 | 1283.40 |
PEG Ratio | - | 2.99 | 2.53 | 0.98 | 19.09 | 19.09 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 14.41 | 14.25 | 13.92 | 16.20 | 7.61 | 9.76 |
EV/EBITDA Ratio | - | 1134.12 | 577.20 | 437.93 | 183.55 | 77.34 |
EV/EBIT Ratio | - | - | 8392.22 | 1253.51 | 555.66 | 98.21 |
EV/FCF Ratio | - | - | 250.60 | 80.26 | 37.30 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.28 | 0.20 | 0.01 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 6.18 | 16.37 | 0.43 | 0.26 | 0.29 | 0.10 |
Debt / FCF Ratio | - | - | 0.19 | 0.05 | 0.06 | - |
Net Debt / Equity Ratio | 0.09 | 0.04 | -0.14 | -0.30 | -0.31 | -0.48 |
Net Debt / EBITDA Ratio | 2.03 | 3.68 | -6.94 | -11.06 | -11.54 | -6.18 |
Net Debt / FCF Ratio | -1.37 | -2.18 | -3.01 | -2.03 | -2.35 | 21.04 |
Asset Turnover | 0.75 | 0.71 | 0.61 | 0.60 | 0.53 | 0.49 |
Inventory Turnover | 1.95 | 1.96 | 1.88 | 2.08 | 2.11 | 2.05 |
Quick Ratio | 0.82 | 0.99 | 1.29 | 2.10 | 2.97 | 4.35 |
Current Ratio | 1.49 | 1.91 | 2.46 | 3.02 | 3.92 | 5.37 |
Return on Equity (ROE) | -15.68% | -3.37% | -1.02% | 1.98% | 0.15% | 5.16% |
Return on Assets (ROA) | 1.14% | -0.46% | 0.06% | 0.48% | 0.46% | 3.02% |
Return on Invested Capital (ROIC) | 2.26% | -1.03% | 0.17% | 1.41% | 0.20% | 11.52% |
Return on Capital Employed (ROCE) | 2.20% | -0.90% | 0.10% | 0.90% | 0.80% | 5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.07% | -0.25% | -0.09% | 0.16% | 0.03% | 0.83% |
FCF Yield | -0.46% | -0.15% | 0.39% | 1.21% | 2.49% | -0.35% |
Buyback Yield / Dilution | -0.07% | -0.13% | -0.04% | 0.24% | 0.76% | -0.05% |